Gasdermins occupy a unique position in the architecture of innate immunity. The family, which in humans includes GSDMA, GSDMB, GSDMC, GSDMD and GSDME, shares a common operational logic. Each protein consists of a cytotoxic N-terminal domain tethered to a C-terminal domain that acts as an internal restraint. In the resting state, the two domains bind each other so that the pore-forming capacity of the N-terminus is masked. When pattern-recognition receptors detect pathogen-associated or damage-associated molecular patterns, they trigger proteolytic cascades—inflammasome assemblies that activate inflammatory caspases such as caspase-1, caspase-4, caspase-5 and caspase-11, and, in apoptotic contexts, caspase-3 or granzyme-mediated cleavage. These enzymes cut the gasdermin at a flexible linker region, releasing the N-terminal fragment. Freed from its autoinhibitory partner, the fragment translocates to the plasma membrane, oligomerizes and inserts a large beta-barrel pore with an inner diameter on the order of 10 to 20 nanometers.

The consequences of pore formation are dramatic and rapid. Ions rush down their electrochemical gradients, water follows osmotically, the cell swells and bursts in the lytic mode of death known as pyroptosis. Before rupture, the pores permit the efflux of potassium and the release of mature interleukin-1beta and interleukin-18, alarmins such as high-mobility group box 1, and other inflammatory cargo that summon and shape the immune response. Pyroptosis is therefore not merely a demolition but a broadcast: the dying cell converts its own destruction into an alarm signal that recruits neutrophils, activates antigen-presenting cells and biases the adaptive immune system toward antiviral effector programs. This dual character—killing and alerting—makes the gasdermin system attractive for therapeutic exploitation, particularly against pathogens that thrive by suppressing or evading conventional immune pathways.

Viruses and gasdermins have long been adversaries in an evolutionary arms race. Many viruses encode inhibitors that block inflammasome sensors, sequester gasdermin fragments or interfere with caspase activation, reflecting the selective pressure that pyroptosis exerts on viral replication. Poxviruses, herpesviruses, influenza viruses and coronaviruses all deploy strategies to dampen inflammatory cell death. Conversely, host cells can route viral sensing signals toward gasdermin activation through multiple sensors, including ZBP1, which detects influenza A virus through recognition of Z-form nucleic acid, and AIM2 or IFI16, which sense foreign DNA. The observation that gasdermin activation can restrict viral replication even when interferon responses are disabled underscores the pathway’s value as a fail-safe. The Cell Research article situates the new engineering efforts within this biological context, arguing that the natural system’s potency has been limited chiefly by its lack of specificity and by viral countermeasures.

Here artificial intelligence changes the calculus. Modern structure-prediction systems such as AlphaFold2 and its successors have resolved the atomic architectures of gasdermin domains, their autoinhibited complexes and their membrane-inserted oligomeric pores, giving designers an accurate map of the conformational switch that governs activity. More consequentially, diffusion-based and language-model-based protein design tools now allow researchers to specify a desired function—a binding interface, a cleavage site, a regulatory logic module—and generate amino acid sequences predicted to fold into structures that fulfill it. Rather than screening natural variants or making incremental mutations, designers can compose gasdermin-based molecules from the ground up, fusing pore-forming domains to sensor modules that respond to molecular features found only in infected cells.

The design logic described in the article follows a gating principle. An engineered construct remains inert until it encounters a virus-specific cue: a viral protease that cleaves a designed linker, a viral RNA or DNA species bound by an engineered sensor domain, or a host-state marker such as a receptor induced by interferon signaling. Only when the gate opens is the gasdermin N-terminal domain released or reconfigured to oligomerize at the membrane. In principle, such constructs could discriminate infected from uninfected tissue with a fidelity that natural inflammasome pathways, which respond to broad danger signals, cannot achieve. The article emphasizes that computational modeling of pore geometry, oligomerization energetics and membrane interactions is essential at every step, because even small deviations in the N-terminal domain can abolish pore formation or, conversely, produce toxic nonspecific membrane binding.

Experimental validation of AI-designed gasdermins, as discussed in the piece, proceeds through iterative cycles in which predicted structures are tested in liposome leakage assays, cell-culture infection models and, ultimately, animal studies. Key metrics include the tightness of the off state, the sensitivity and specificity of the trigger response, the efficiency of membrane pore formation and the immunological consequences of pyroptotic lysis in vivo. The authors highlight that design failures are informative: constructs that leak activity reveal the energetic margins of autoinhibition, while constructs that fail to activate expose weaknesses in sensor-linker coupling. Each cycle feeds data back into the design pipeline, a workflow that has already accelerated progress in other classes of engineered proteins, including designed cytokines, antibody mimetics and switchable cell-death regulators.

The therapeutic implications extend across antiviral medicine and beyond. A programmable gasdermin could, in principle, be delivered as a gene therapy or mRNA therapeutic to tissues vulnerable to a specific pathogen, standing ready to eliminate infected cells before viral spread becomes established. Such an approach would be particularly valuable against emerging viruses for which vaccines and antivirals lag behind outbreak speed, and against chronic infections where viral evasion of immune clearance is the central obstacle. The same design principles could be adapted to oncology, since many tumors evade pyroptosis by silencing gasdermin expression or downregulating inflammasome components, and engineered constructs triggered by tumor-specific proteases or neoantigens could restore an inflammatory form of cancer-cell death that promotes antigen release and immune priming. The article notes that the concept of AI-guided cell-death engineering generalizes: gasdermins are one member of a broader class of pore-forming effectors, including the immune proteins MLKL in necroptosis and the complement membrane-attack complex, whose activity might similarly be placed under synthetic control.

Substantial challenges temper the enthusiasm. Uncontrolled pyroptosis is dangerous: excessive gasdermin activation drives cytokine storms, tissue damage and septic shock, as demonstrated by the lethal inflammation observed when gasdermin pores open unchecked during severe infections. Any engineered system must therefore incorporate fail-safes, such as dependence on multiple simultaneous triggers, dose-limiting delivery strategies and pharmacological off switches. Immune responses against designed protein sequences pose another obstacle, as does the difficulty of achieving tissue-restricted expression. Off-target activation in bystander cells, even at low frequency, could produce disproportionate inflammation given the potency of the pore-forming mechanism. The authors stress that computational predictions, however accurate, must be paired with rigorous empirical safety testing across diverse cell types and inflammatory contexts before clinical translation can be contemplated.

Nevertheless, the trajectory is clear. The gasdermin system, once understood only as a blunt instrument of innate defense, is becoming a designable platform. Artificial intelligence supplies the structural insight and generative capacity to reprogram its trigger logic, its target selectivity and even its pore properties, while the underlying biology supplies a death mechanism that is fast, inflammatory and inherently immunogenic—qualities well suited to antiviral defense. The Cell Research article frames this convergence as the beginning of a programmable immunology, in which the executioners of cell death are no longer merely triggered by infection but are deliberately built to seek it out. If the engineering challenges of specificity, control and delivery can be met, AI-guided gasdermins may transform the treatment of viral disease from a defensive struggle into a precise, pre-emptive campaign against the cells that harbor the enemy.

Subject of Research: AI-guided engineering of gasdermin proteins to induce pyroptotic death of virus-infected cells

Article Title: Programmed to kill: AI-guided gasdermins eliminate virus-infected cells

Article References: Betrancourt, A., & Broz, P. (2026). Programmed to kill: AI-guided gasdermins eliminate virus-infected cells. Cell Research. https://doi.org/10.1038/s41422-026-01292-y

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01292-y

Keywords: gasdermin, pyroptosis, AI protein design, innate immunity, virus-infected cells, inflammasome, cell death, antiviral therapy, protein engineering, pore-forming proteins, Cell Research, immunotherapy

The central achievement of the work is the determination of cryo-electron microscopy structures of human NLRP6 in two distinct conformational states: one in which ATP is bound within the nucleotide-binding domain, and one in which that domain is unoccupied. Capturing a signaling protein of this complexity in more than one state is a technical tour de force. NLRP6 belongs to the NOD-like receptor family, whose members are built from a modular architecture that includes a pyrin domain for downstream signaling, a central nucleotide-binding oligomerization domain, or NBD, and a leucine-rich repeat region that is thought to sense activating cues. In the resting state, these modules are folded against one another in a self-suppressed arrangement; upon activation, the protein must rearrange dramatically to oligomerize and recruit downstream adaptors. Cryo-EM is uniquely suited to visualizing both the compact monomeric states and the extended oligomeric assemblies that NLR-family proteins adopt along this trajectory.

What the structures reveal is that ATP is not merely a passive occupant of the nucleotide-binding pocket but an active participant in the regulatory logic of the receptor. By binding within the NBD, ATP stabilizes a conformation of NLRP6 in which the domains are locked together in an arrangement that precludes the transitions required for inflammasome assembly. In effect, the nucleotide acts as a molecular latch. The comparison between the ATP-bound and ATP-unbound conformations allowed the researchers to trace precisely which intramolecular contacts shift when the nucleotide engages the pocket, and how those shifts propagate through the protein to restrain the regions that would otherwise mediate self-association and filament formation.

This finding carries considerable conceptual weight because nucleotide binding has historically been viewed primarily through the lens of activation in this protein family. Many NLR proteins require ATP binding or hydrolysis for their oligomerization and signaling functions, and ATP or its analogues have often been used experimentally to promote the assembly of inflammasome complexes in vitro. The new structures of NLRP6 invert that expectation for this particular receptor, identifying ATP as a stabilizer of the inactive, monomeric state rather than a driver of oligomerization. The work thus adds an important nuance to the general model of NLR regulation: the effect of nucleotide binding is not uniform across the family, and it must be understood receptor by receptor, in structural terms, rather than assumed.

The mechanistic detail extracted from the structures is substantial. By comparing the two conformational states at high resolution, Cui and colleagues could identify the specific structural elements that respond to ATP occupancy. These include regions of the NBD that reposition relative to the adjacent regulatory domains, contacts that either form or dissolve depending on whether the nucleotide is present, and hinge-like segments whose mobility governs whether the protein can escape its autoinhibited fold. Such residue-level information is precisely what is needed to design targeted experiments, and indeed the study is framed around structure-guided biochemical validation of the observed interactions, a standard that has become the norm for mechanistic structural biology of innate immune receptors.

The broader context of this work is the intense interest in the NLRP family of inflammasome sensors, and in NLRP3 in particular, as drug targets. Overactive inflammasome signaling has been implicated in a wide range of human diseases, from gout and atherosclerosis to neurodegeneration and inflammatory bowel disease. NLRP6, which is especially prominent in epithelial tissues such as the intestine, has emerged as a key regulator of mucosal immunity and of the interplay between the host and the microbiome. Understanding how NLRP6 is held in its inactive state therefore has implications that extend well beyond basic receptor biology, touching on the architecture of the intestinal barrier and the maintenance of a healthy relationship with the microbial communities that inhabit it.

From a structural biology standpoint, the study also exemplifies the current maturity of cryo-electron microscopy as a method for dissecting regulatory mechanisms in immune proteins. A decade ago, obtaining structures of a large, flexible, multidomain receptor in even one state would have been a career-defining effort. Today, as this work demonstrates, it is feasible to capture the same protein in multiple functional states and to compare them directly, transforming what was once a static portrait of a protein into something closer to a molecular film. The two NLRP6 structures together form precisely such a comparison: one frame showing the nucleotide-engaged, inhibited receptor, another showing the conformation from which activation must proceed.

The identification of ATP as an endogenous inhibitor also raises intriguing questions about how intracellular nucleotide levels tune inflammasome sensitivity. Cells experience fluctuations in ATP availability under stress, during metabolic shifts, and in the course of infection. If ATP occupancy of the NLRP6 nucleotide pocket keeps the receptor in a signaling-competent-off state, then changes in cellular energy status could, in principle, translate into changes in the threshold at which NLRP6 fires. Whether such metabolic regulation operates in living cells, and how it intersects with the other inputs that NLRP6 senses, are questions that the structural work now makes experimentally accessible. The structures provide a concrete physical hypothesis that cell biological and biochemical studies can test directly.

For the growing community of researchers attempting to develop inflammasome-directed therapeutics, the study offers a template. Drugs that stabilize an autoinhibited conformation, or that mimic the effect of ATP binding, could in principle dampen pathological NLRP6 signaling. Conversely, understanding exactly which interactions must break for activation to occur points to where small molecules might lock the receptor open, should augmentation of NLRP6-dependent immunity ever be clinically desirable. The structural map produced by Cui and colleagues converts those goals from abstract ambitions into chemically addressable problems, listing the pockets, interfaces, and conformational switches that any future drug would need to engage. In a field where the therapeutic stakes are high and the molecular targets are notoriously difficult to control, that kind of precision is exactly what progress looks like.

Subject of Research: Structural mechanism of ATP-mediated inhibition of the human NLRP6 inflammasome revealed by cryo-electron microscopy.

Article Title: Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome

Article References: Cui, Z., Sheng, Q., Son, M., Goo, Y. A., & Shen, C. (2026). Structural mechanisms for ATP-mediated inhibition of human NLRP6 inflammasome. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01878-5

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01878-5

Keywords: NLRP6, inflammasome, ATP, cryo-EM, innate immunity, NOD-like receptors, structural biology, inflammation, NBD, immune regulation, intestinal immunity, autoinhibition

Inflammasomes are cytosolic signaling complexes assembled by pattern recognition receptors in response to a wide array of danger-associated and pathogen-associated molecular patterns. Among the best characterized is the NLRP3 inflammasome, which can be activated by an extraordinary diversity of stimuli, ranging from extracellular ATP and crystalline substances such as monosodium urate to perturbations in cellular homeostasis including mitochondrial dysfunction and ionic flux. Structural studies, notably cryo-electron microscopy analyses, have revealed that NLRP3 oligomerizes into a large ring-like platform that recruits the adaptor protein ASC through pyrin domain interactions. ASC in turn nucleates the polymerization of procaspase-1 filaments through its caspase recruitment domain, creating a branched, star-shaped assembly that has become iconic in the field of innate immunity.

The review emphasizes how this hierarchical assembly process, in which a receptor seeds adaptor polymerization which then seeds effector activation, is a recurring architectural principle across inflammasome families. DNA-sensing receptors such as AIM2 and the Pyrin family of receptors, as well as the more recently described sensors like NLRP1 and CARD8, all converge on the same downstream machinery despite recognizing fundamentally different ligands. This convergence explains how a limited set of adaptor and effector molecules can translate an enormous diversity of upstream danger signals into a uniform cellular response: the activation of inflammatory caspases, cleavage of the cytokine precursors pro-interleukin-1 beta and pro-interleukin-18, and induction of a lytic form of cell death known as pyroptosis.

Pyroptosis itself has been structurally dissected at the level of its executioner, gasdermin D. Activated inflammatory caspases cleave gasdermin D to release an N-terminal fragment that oligomerizes into membrane pores, causing osmotic lysis and the release of intracellular contents, including mature interleukin-1 beta. Recent structures of gasdermin pores have clarified how the positively charged face of the oligomer interacts with membrane lipids and how pore formation is regulated. This level of mechanistic detail has direct pharmacological implications, because small molecules that block gasdermin pore formation or inflammasome assembly could dampen pathological inflammation in conditions as varied as gout, atherosclerosis, type 2 diabetes, inflammatory bowel disease, and neurodegenerative disease, all of which have been linked to excessive inflammasome activity.

Beyond canonical inflammasomes, the review devotes substantial attention to PANoptosis, a recently articulated form of inflammatory programmed cell death that integrates features of pyroptosis, apoptosis, and necroptosis within a single, coordinated complex termed the PANoptosome. Unlike a classical inflammasome, a PANoptosome contains components from multiple cell death pathways simultaneously, including Z-DNA-binding protein 1, or ZBP1, which senses Z-form nucleic acids generated during viral infection, together with receptor-interacting protein kinases and other death-domain proteins. Structural and biochemical studies suggest that these complexes assemble through a web of homotypic and heterotypic domain interactions, creating a platform capable of activating multiple death effector machineries in parallel and amplifying inflammatory signaling to a degree that neither pathway could achieve alone.

ZBP1 has emerged as a particularly instructive example of how structural insights inform PANoptosome biology. Its two Z-nucleic acid binding domains recognize the unusual left-handed conformation of Z-DNA and Z-RNA, which accumulates in cells infected with viruses such as influenza A. Upon ligand binding, ZBP1 engages RIPK3 through RHIM domain interactions, and in certain contexts also recruits NLRP3 and ASC, thereby coupling viral sensing directly to necroptosis, pyroptosis, and cytokine release. Mutations that disrupt these interactions protect mice from lethal influenza-associated inflammation, underscoring the in vivo importance of this pathway and highlighting RHIM-mediated interactions as a potential drug target in severe viral pneumonia and other contexts of pathogenic inflammation.

One of the central themes of the review is that autoinhibition is a universal feature of innate immune sensors, reflecting the danger of accidental self-destruction if these potent inflammatory pathways are triggered spuriously. NLRP3, for example, is held in an inactive conformation by its LRR domain folding back onto the nucleotide-binding domain, a constraint released through a multi-step activation process involving NEK7 binding, deubiquitination, and translocation to the Golgi or endosomal membranes. Similar autoinhibitory mechanisms govern NLRP1, which releases its inhibitory function upon proteasomal degradation of an N-terminal regulatory segment, and pyrin, which is restrained by phosphorylation-dependent sequestration through binding to 14-3-3 proteins. Structural biology has provided atomic-level explanations for how disease-associated mutations, including those causing cryopyrin-associated periodic syndromes and familial Mediterranean fever, destabilize these autoinhibited states and drive constitutive inflammasome activation.

The therapeutic implications of this structural knowledge are considerable and span several classes of intervention. Direct inhibitors of NLRP3, such as MCC950 and its derivatives, have demonstrated efficacy in preclinical models of numerous inflammatory diseases and are progressing through clinical evaluation. Second-generation approaches include compounds that block ASC speck formation, inhibitors of inflammatory caspases, gasdermin D antagonists designed to prevent pore formation, and agents targeting upstream cytokine signaling through blockade of interleukin-1 family receptors. For PANoptosome-driven diseases, particularly severe viral infections and certain hereditary autoinflammatory syndromes, strategies that interrupt specific protein-protein interfaces, such as the RHIM-dependent interaction between ZBP1 and RIPK3, represent an emerging frontier. The review argues that structural data, by revealing precisely where and how these complexes assemble, will be indispensable for the rational design of such inhibitors.

Challenges nonetheless remain substantial. Inflammasome components are large, flexible, and often membrane-associated, complicating structural determination of full assemblies in physiologically relevant states. Much of the available structural information derives from isolated domains, truncated constructs, or oligomers assembled in vitro, and bridging the gap between these reductionist structures and the behavior of intact complexes in living cells remains a priority. Moreover, the redundancy and interconnection of inflammatory cell death pathways mean that blocking one arm may simply redirect signaling through another, arguing for combination approaches informed by a systems-level understanding of PANoptosome architecture and regulation.

Taken together, the review frames inflammasomes and PANoptosomes not as isolated curiosities of innate immunity but as a structurally unified family of molecular decision-making machines whose misregulation underlies a broad spectrum of human disease. As cryo-electron microscopy, cryogenic electron tomography, and single-molecule imaging continue to reveal these assemblies at ever higher resolution in increasingly native contexts, the prospect of precisely targeted anti-inflammatory therapeutics, capable of silencing pathological inflammation while preserving beneficial host defense, moves steadily closer to reality.

Subject of Research: Structural and mechanistic analysis of innate immune sensors that assemble inflammasomes and PANoptosomes

Article Title: Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications

Article References: Upadhyay, S., Nagampalli, R., Resende, S., & Kanneganti, T.-D. (2026). Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications. Cell Research. https://doi.org/10.1038/s41422-026-01287-9

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01287-9

Keywords: innate immunity, inflammasome, PANoptosis, PANoptosome, NLRP3, ZBP1, ASC, caspase-1, gasdermin D, pyroptosis, structural biology, anti-inflammatory therapeutics

The study, titled ‘Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques,’ examines how removing this single kinase alters the metabolic machinery inside macrophages and, as a consequence, changes the inflammatory character of atherosclerotic lesions. The finding is notable because it links three areas that have usually been studied in isolation: kinase signaling, immunometabolism, and the inflammatory form of cell death known as pyroptosis. By connecting them, the work suggests that a pathway long associated with immune activation may instead be a liability in chronic vascular disease.

To understand why this matters, it helps to recall what macrophages do inside an artery wall. These cells are recruited to sites where low-density lipoprotein particles have accumulated beneath the endothelial lining. Once there, they engulf lipids, and in doing so they can become the foam cells that give early plaques their fatty appearance. But macrophages are not passive containers. They are metabolically active, decision-making cells whose internal fuel choices, whether to burn glucose rapidly through glycolysis, whether to rely on mitochondrial oxidative phosphorylation, whether to draw on fatty acid oxidation, shape the inflammatory signals they emit. A plaque dominated by pro-inflammatory macrophages tends to be rich in degradative enzymes and death signals, thinning its protective fibrous cap and raising the risk of rupture.

Pyroptosis is one of the most incendiary of those death signals. Unlike ordinary apoptosis, which quietly packages cellular debris for removal, pyroptosis is a lytic, inflammatory death driven by the activation of inflammasomes, multiprotein complexes that trigger caspase enzymes to cleave gasdermin proteins. Cleaved gasdermins form pores in the cell membrane, causing the cell to swell, burst, and spill its contents, including potent inflammatory messengers such as interleukin-1 family cytokines, into the surrounding tissue. Within a plaque, waves of pyroptotic macrophage death enlarge the necrotic core, weaken the fibrous cap, and promote the thrombus formation that turns a stable lesion into a clinical emergency.

Protein kinase C delta has long been recognized as a versatile signaling molecule in immune cells, participating in pathways that regulate activation, migration, and death decisions. The new research asked a direct question: what happens to macrophage behavior, and to atherosclerotic disease, when this kinase is missing? The answer, according to the study, is that deficiency of the kinase reprograms macrophage immunometabolism, shifting the internal metabolic set points of the cells in a direction that suppresses pyroptosis. In other words, without protein kinase C delta, macrophages appear to become less prone to the explosive inflammatory death that destabilizes plaques.

The concept of immunometabolic reprogramming is central to interpreting this result. Macrophages adopt broadly distinguishable metabolic profiles depending on their activation state, and these profiles are not merely byproducts of inflammation; they actively reinforce it. A glycolytic shift, for example, supports the rapid production of inflammatory mediators, while a more oxidative, mitochondrial-oriented metabolism tends to accompany reparative, tissue-tolerant behavior. By showing that removing protein kinase C delta rewrites these metabolic choices, the study positions the kinase as a kind of metabolic gatekeeper whose activity licenses the inflammatory, pyroptosis-prone phenotype in the plaque environment.

The downstream consequence reported in the work is plaque stabilization. In atherosclerosis research, stability is assessed through structural features: the thickness of the fibrous cap that separates the thrombogenic necrotic core from the bloodstream, the size of that necrotic core, the collagen content of the cap, and the burden of dead and dying cells within the lesion. A plaque that retains a thick cap, a modest necrotic core, and abundant collagen is far less likely to rupture than one riddled with pyroptotic debris. The finding that PKC delta deficiency suppresses pyroptosis and stabilizes plaques implies that the kinase contributes to precisely the features that make lesions dangerous, and that its removal tilts lesions toward a safer architecture.

These results arrive amid a broader reassessment of inflammation as a therapeutic target in cardiovascular medicine. Landmark clinical trials have already demonstrated that blunting inflammatory signaling, for instance through interleukin-1 beta blockade or colchicine treatment, reduces cardiovascular events in selected patients, validating the idea that the immune component of atherosclerosis is druggable. Against that backdrop, a kinase that governs whether plaque macrophages die inflammatory deaths is an attractive candidate for intervention, because it acts upstream of the terminal events, inflammasome activation, gasdermin pore formation, cytokine release, and necrotic core expansion, that directly damage plaque integrity.

At the same time, the study invites caution. Protein kinase C delta participates in many physiological processes beyond the plaque, including immune defense against infection, platelet function, and the regulation of cell survival in multiple tissues. Any therapeutic strategy aimed at inhibiting the kinase, or at exploiting the metabolic programs it controls, would need to weigh the benefit of calmer plaque macrophages against the risk of impairing the host responses that depend on this enzyme. Translating a reprogramming effect observed in experimental models into a safe clinical approach will require a detailed map of which downstream metabolic and inflammasome pathways mediate the protection, and whether those pathways can be targeted selectively.

Even so, the conceptual contribution is substantial. The work reframes atherosclerotic plaque stability not simply as a matter of lipid lowering, which remains the foundation of therapy, but as a matter of immune cell fate, decided by intracellular metabolic wiring that can be shifted by manipulating a single signaling node. If the findings hold up across models and, eventually, in human tissue, they suggest that future treatment could combine lipid management with agents that nudge plaque macrophages away from pyroptosis and toward a stable, reparative state. In a disease that kills millions each year largely through plaque rupture, teaching immune cells to keep their composure may prove to be one of the more consequential ideas in modern cardiovascular research.

Subject of Research: The role of protein kinase C delta deficiency in reprogramming macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques

Article Title: Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques

Article References: Lien, C.-F., Chang, H.-Y., Yu, S.-H., Cho, R.-L., Chen, S.-J., Kuo, T.-T., Chong, P. C.-T., Ye, C.-H., Lin, F.-Y., Wu, W.-L., Lin, S.-H., Tsai, C.-S., & Lin, C.-S. (2026). Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01842-9

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01842-9

Keywords: protein kinase C delta, macrophages, immunometabolism, pyroptosis, atherosclerosis, plaque stability, inflammasome, foam cells, cardiovascular disease, inflammation, Deficiency, protein

The significance of the finding lies in the peculiar architecture of NLRP3 itself. Like other members of the NOD-like receptor family, NLRP3 is built from a pyrin domain at its amino terminus, a central NACHT nucleotide-binding domain, helical domain 2, and a carboxy-terminal leucine-rich repeat region. Structural work over the past several years, including cryo-electron microscopy studies of full-length NLRP3, has revealed that in its resting state the protein folds back on itself into a compact, ADP-bound, cage-like conformation. The leucine-rich repeats wrap around the NACHT domain, and multiple intramolecular contacts lock the receptor into an autoinhibited state. This autorepression is essential for preventing spurious inflammation, but it also creates a puzzle: activating stimuli as chemically and physically diverse as nigericin, ATP, crystalline silica and imiquimod do not bind NLRP3 directly. Something else inside the cell must physically pry the receptor open, and until now, that something had not been convincingly identified.

To find it, the team took an unbiased approach. Using two complementary screening strategies, including mass spectrometry of ASC immunoprecipitates and insoluble complexes isolated from activated immune cells, they searched for proteins that associate with the NLRP3 inflammasome during activation. Among the hits that emerged was AMBRA1, short for activating molecule in Beclin1-regulated autophagy protein 1. AMBRA1 was already a familiar name in cell biology, having first been characterized as a regulator of autophagy and nervous system development, and more recently implicated in the control of D-type cyclins through cullin-RING ubiquitin ligase complexes. Its appearance in the NLRP3 proteome suggested an entirely unexpected second career for the protein. The researchers confirmed that AMBRA1 is a genuine constituent of the NLRP3 inflammasome complex, co-localizing with NLRP3 and ASC specks in stimulated cells.

The functional evidence was immediate and compelling. When the researchers deleted AMBRA1 from human THP-1 monocytic cells or from murine immortalized bone marrow-derived macrophages, NLRP3 activation collapsed. Cells lacking AMBRA1 failed to form ASC specks efficiently, showed reduced cleavage of caspase-1 and gasdermin D, and secreted far less interleukin-1β in response to nigericin, ATP and silica dioxide. Importantly, the defect was selective. Activation of the related NLRP1 inflammasome, triggered by the drug Val-boroPro, and AIM2 inflammasome activation induced by cytosolic DNA via poly(dA:dT) proceeded normally in AMBRA1-deficient cells, indicating that AMBRA1 is not a general requirement for inflammasome assembly but a specific cofactor for NLRP3. Reconstituting the knockout cells with full-length AMBRA1 restored inflammasome activity, cementing the causal relationship.

Delving into mechanism, the team demonstrated that AMBRA1 acts through direct physical binding to NLRP3. Using a combination of co-immunoprecipitation, in vitro protein interaction assays and fluorescence lifetime imaging microscopy-based Förster resonance energy transfer, they showed that AMBRA1 engages two specific subdomains of NLRP3: the leucine-rich repeat region and helical domain 2. The AMBRA1 surface responsible for this engagement involves its β-propeller domain together with an N-terminal helical region. Structural modeling, informed by AlphaFold 3-based predictions and supported by biochemical validation, revealed a large interaction interface burying roughly 3900 square angstroms of surface area, with the AMBRA1 β-propeller and N-terminal helix inserting into the concave face of the NACHT-LRR region of NLRP3.

The allosteric consequences of this binding are the heart of the discovery. By comparing structural models of AMBRA1-bound NLRP3 with the established inactive conformation, the researchers found that AMBRA1 engagement destabilizes the intertwined LRR assembly and promotes detachment of the interlocked NACHT subdomains. In other words, AMBRA1 physically pries apart the contacts that hold NLRP3 in its closed, ADP-bound, autoinhibited cage. Once the receptor is loosened, the nucleotide-binding pocket becomes accessible, and the team showed that AMBRA1 facilitates the binding of ATP to NLRP3. Nucleotide exchange and hydrolysis then drive the global conformational rearrangement that exposes oligomerization interfaces and the pyrin domain, allowing NLRP3 to multimerize, recruit the adaptor ASC, and launch the caspase-1 cascade. The authors draw an instructive parallel to Apaf-1, the apoptosome scaffold, which is likewise held inactive by an intramolecular interaction between its amino-terminal region and a WD40 β-propeller and is opened by binding of cytochrome c between its propellers. AMBRA1, in this scheme, plays a role for NLRP3 conceptually analogous to that of cytochrome c for Apaf-1, a conserved strategy of scaffold-mediated release from autoinhibition.

The study also clarified how AMBRA1 fits into the established, multistep model of NLRP3 activation. Prior work from the same collaborative group had shown that signal-induced phase separation of NLRP3 initiates inflammasome assembly, and other laboratories had defined roles for NEK7 licensing, trans-Golgi recruitment via phosphatidylinositol-4-phosphate, palmitoylation by ZDHHC enzymes, and deubiquitination by BRCC3. The new data indicate that AMBRA1 operates at the conformational opening step, acting as a scaffold that both promotes NLRP3 condensation and oligomerization and enables the transition to the ATP-bound active state. Genetic experiments showed that AMBRA1 deficiency did not disrupt upstream events such as priming of NF-κB signaling, dispersal of the trans-Golgi network, or lysosomal damage, pinpointing its action squarely at the level of NLRP3 itself. Notably, the interaction between AMBRA1 and NLRP3 was unaffected by the clinical-stage NLRP3 inhibitor MCC950, suggesting the two regulatory mechanisms are distinct.

The physiological stakes were tested in mouse models. Myeloid-cell-specific AMBRA1 knockout mice, generated using a Lyz2-Cre driver, showed markedly reduced inflammatory responses in three preclinical settings: endotoxic shock induced by lipopolysaccharide, dextran sulfate sodium-induced colitis, and polymicrobial sepsis. In the colitis model, animals lacking AMBRA1 in myeloid cells were protected from the weight loss and colon shortening that characterize the disease, phenocopying the protection seen in Nlrp3-deficient mice. These results position AMBRA1 as a genuine driver of NLRP3-dependent pathology in vivo, not merely a biochemical curiosity.

Perhaps the most translationally exciting aspect of the work is therapeutic. The team screened nanobodies, the single-domain antibodies derived from camelids, against AMBRA1 using a yeast surface display platform. Several nanobodies targeting the N-terminal helical region of AMBRA1, including Nb27, Nb14 and Nb35, blocked the AMBRA1-NLRP3 interaction and potently inhibited NLRP3 activation and interleukin-1β release in response to nigericin and to Salmonella typhimurium infection. Because the interface is a defined protein-protein contact rather than an enzymatic active site, it offers a structurally characterized target for small molecules or engineered biologics aimed at taming NLRP3-driven inflammation. Given the involvement of this inflammasome in gout, atherosclerosis, type 2 diabetes, Alzheimer’s disease, inflammatory bowel disease and sepsis, a validated molecular switch at the heart of NLRP3 activation could reshape the search for next-generation anti-inflammatory drugs.

The discovery also reframes AMBRA1 itself. A protein celebrated for coordinating autophagy initiation, dynein-dependent trafficking of autophagosomes and cyclin D degradation now stands revealed as a bifunctional regulator straddling two of the cell’s most fundamental stress responses: self-digestion and inflammation. How cells coordinate AMBRA1’s commitments between these pathways, and whether autophagy-related post-translational modifications tune its inflammasome-scaffolding activity, are questions the field will now pursue. What is already clear is that the autoinhibited cage of NLRP3 has a lock, and the key has finally been found.

Subject of Research: Allosteric activation of the NLRP3 inflammasome by the autophagy adaptor protein AMBRA1

Article Title: AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition

Article References: Pan, M., Zhou, J., Fu, S., Tang, Y., Zou, G., Li, P., & Jiang, Z. (2026). AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition. Nature Immunology. https://doi.org/10.1038/s41590-026-02644-x

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02644-x

Keywords: NLRP3, AMBRA1, inflammasome, innate immunity, allosteric activation, autoinhibition, interleukin-1β, pyroptosis, autophagy, nanobodies, inflammation, sepsis